HK1216992A1 - 穩定的人生長激素液體製劑 - Google Patents

穩定的人生長激素液體製劑

Info

Publication number
HK1216992A1
HK1216992A1 HK16104967.3A HK16104967A HK1216992A1 HK 1216992 A1 HK1216992 A1 HK 1216992A1 HK 16104967 A HK16104967 A HK 16104967A HK 1216992 A1 HK1216992 A1 HK 1216992A1
Authority
HK
Hong Kong
Prior art keywords
growth hormone
liquid formulation
human growth
stable liquid
stable
Prior art date
Application number
HK16104967.3A
Other languages
English (en)
Inventor
金仙姬
鄭堯景
張裁榮
李相吉
李玟錫
朴勝國
Original Assignee
Daewoong Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Co Ltd filed Critical Daewoong Co Ltd
Publication of HK1216992A1 publication Critical patent/HK1216992A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104967.3A 2006-07-06 2016-04-29 穩定的人生長激素液體製劑 HK1216992A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/KR2006/002640 WO2008004717A1 (en) 2006-07-06 2006-07-06 A stable liquid formulation of human growth hormone
CNA2006800556995A CN101505789A (zh) 2006-07-06 2006-07-06 稳定的人生长激素液体制剂

Publications (1)

Publication Number Publication Date
HK1216992A1 true HK1216992A1 (zh) 2016-12-16

Family

ID=38894670

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104967.3A HK1216992A1 (zh) 2006-07-06 2016-04-29 穩定的人生長激素液體製劑

Country Status (11)

Country Link
US (1) US8409586B2 (zh)
EP (1) EP2049148B1 (zh)
JP (1) JP5180202B2 (zh)
CN (1) CN101505789A (zh)
BR (1) BRPI0621841B8 (zh)
ES (1) ES2605022T3 (zh)
HK (1) HK1216992A1 (zh)
HU (1) HUE031329T2 (zh)
LT (1) LT2049148T (zh)
PT (1) PT2049148T (zh)
WO (1) WO2008004717A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
UA108994C2 (uk) * 2009-11-17 2015-07-10 Ипсен Фарма С.А.С. Фармацевтична композиція, що містить комбінацію hgh і rhigf-1, і процес її приготування (варіанти)
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
JP6166470B2 (ja) * 2013-11-12 2017-07-19 カディラ ヘルスケア リミティド ゴナドトロピンのための新規製剤
US9908976B2 (en) 2015-03-18 2018-03-06 Psmg, Llc Stable polyethylene glycol particle dispersions and methods for forming the stable dispersions
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61296598A (ja) 1985-06-21 1986-12-27 Mitsubishi Electric Corp Ｍｏｓダイナミツクｒａｍのダミ−ワ−ド線駆動回路
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
ATE359824T1 (de) 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
KR970006498A (ko) 1995-07-31 1997-02-21 유충식 활성형 인성장호르몬의 정제 방법
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
KR100210840B1 (ko) 1996-12-24 1999-07-15 구본준 기계 화학적 연마 방법 및 그 장치
KR19990001217A (ko) 1997-06-13 1999-01-15 윤종용 스탠바이 모드에서의 시스템 구동방법 및 장치
JP3723857B2 (ja) 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
KR100573704B1 (ko) 1998-12-02 2006-07-21 동아제약주식회사 인성장 호르몬의 안정화된 액상제제_
EP1220682B1 (en) * 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
CN1284603C (zh) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 杂双官能聚乙二醇衍生物和它们的制备方法
WO2002000261A2 (en) * 2000-06-26 2002-01-03 Monsanto Technology Llc Surfactant-containing formulations for extended release of somatotropin
CN1668332A (zh) * 2002-07-09 2005-09-14 桑多斯股份公司 包含苯酚的含高浓度人生长激素的液体制剂
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution
KR100537260B1 (ko) 2003-09-03 2005-12-19 한미약품 주식회사 인간 성장 호르몬의 안정화된 액상 제제용 조성물
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2540172A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
DE10355189B4 (de) 2003-11-26 2015-04-30 Johnson & Johnson Medical Gmbh Verfahren zum Herstellen eines chirurgischen Implantats sowie chirurgisches Implantat
WO2005063298A1 (en) * 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation

Also Published As

Publication number Publication date
PT2049148T (pt) 2016-12-30
BRPI0621841B8 (pt) 2021-05-25
EP2049148A1 (en) 2009-04-22
US8409586B2 (en) 2013-04-02
ES2605022T3 (es) 2017-03-10
CN101505789A (zh) 2009-08-12
JP2009542629A (ja) 2009-12-03
EP2049148A4 (en) 2013-12-11
WO2008004717A1 (en) 2008-01-10
BRPI0621841A2 (pt) 2011-12-20
EP2049148B1 (en) 2016-09-28
US20090298768A1 (en) 2009-12-03
JP5180202B2 (ja) 2013-04-10
WO2008004717A9 (en) 2013-08-29
BRPI0621841B1 (pt) 2020-12-29
LT2049148T (lt) 2016-11-25
HUE031329T2 (hu) 2017-07-28

Similar Documents

Publication Publication Date Title
HK1216992A1 (zh) 穩定的人生長激素液體製劑
EP2593084A4 (en) LIQUID FORMULATION FROM HUMAN GROWTH HORMONE CONJUGATES WITH LONG-TERM EFFECT
ZA200904544B (en) Stable S-(+)-abscisic acid liquid and soluble granule formulations
EP2081502B8 (en) A medical device for attaching tissue to bone
PL2007356T3 (pl) Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonka
HK1181633A1 (zh) 醫療裝置的內鏡運送
EP1942981A4 (en) DISTRIBUTION OF MEDIUM TO TISSUE
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
PL1570866T3 (pl) Sposób dostarczania płynnego środka sterylizującego do sterylizatora
HK1200019A1 (zh) 用於口腔粘膜給藥的液體變態反應性疫苗製劑的用途
HK1142536A1 (en) Gel useful for the delivery of cosmetic active ingredients
ZA200900125B (en) Liquid formulation of pyrethroids
ZA200704926B (en) Modified human growth hormone
HK1131546A1 (en) Subcutaneous implants releasing an active principle over an extended period of time
IL213711A (en) Nano-phenofibrate preparation
IL195034A0 (en) Liquid pharmaceutical formulation
EP2073631A4 (en) AGROCHEMICAL FORMULATIONS OF LIQUID CRYSTALS
HK1215930A1 (zh) 穩定的人生長激素液體製劑
IL199756A0 (en) Medically active plaster
GB0813004D0 (en) Stable therapeutic formulation of human growth hormone
HK1144295A1 (en) Stable liquid formulation
GB2451360B (en) Hormone replacement formulation
EP2005955A4 (en) UNSATURATED SALT FORMULATION OF AMPELOPSIN AND CORRESPONDING APPLICATION
GB0610207D0 (en) New forms of active pharmaceutical ingredient
ZA200806439B (en) Stable dosage formulations of imidazolylalkyl-pyridines